

QIBA PET Amyloid Biomarker Committee

17 July 2015 at 9:00 AM CT (GMT-6)

Call Summary

Notes provided by Dr. Anne Smith

In attendance:

<i>Anne Smith, PhD (Co-Chair)</i>	Gregory Klein, PhD	Charles Smith, MSCS	RSNA Fiona Miller
Kirk Frey, MD, PhD	Dawn Matthews, MS, MBA	John Sunderland, PhD	Julie Lisiecki
Paul Kinahan, PhD, FIEEE	Amy Perkins, PhD	Jean-Luc Vanderheyden, PhD	

Agenda for QIBA PET Amyloid Netmeeting

August 14, 2015

Anne Smith, Netmeeting lead

Action Items

- ALL:** read Profile and send feedback via Excel spreadsheet to Eric (ericasperlman@gmail.com) by **September 11, 2015**
 - Paul and John to submit their Round 4 project update to Amyloid co-chairs and RSNA staff by Aug. 31.
 - Paul and John will consider presenting a poster at RSNA's QIBA Section
 - If possible, Rathan to give update on test-retest subgroup progress at next PET Amyloid BC **Sep. 11 Netmeeting**
 - Greg will review Profile and give feedback for the Site Qualification Section
 - Greg will also work with Bob Koeppel to include recommendations/specifications for standalone PET scanners that use 68-Ge transmission sources
 - Dawn will review Profile and give feedback for the Image Analysis Section
 - In particular, will edit the Centiloid section per the comments below
 - Also make clear that we do NOT recommend PVC in this version (see comments below)
 - Will also review Section 4.4 Performance assessment: Image Analysis Workstation
 - Anne to find volunteer from Avid/Lilly, GE, Piramal and Navidea to review the Subject Preparation & Exam Performance with Radiotracer: if interested, please send her an Email (anne.m.smith@siemens.com)
 - RSNA staff to supply a list of organizations/individuals who may want to review our Profile to
 - the co-chairs, similar to what was done for the FDG Tumor Profile
 - Consider adding GAAIN (<http://gaain.org/>) to this list (MOU with QIBA attached)
- General dates and deadlines
 - Status update on Round 4 projects deadline: **Aug. 31**
 - Please send to Amyloid co-chairs and RSNA Staff by this date
 - No option for a no-cost continuation!
 - NIBIB funding for Round 5 does depend on the timely completion of these reports
 - Update/request from Paul Kinahan re phantom-DRO project
 - Paul and John will submit their report by Aug. 31**
 - Status update on Round 5 submitted projects:
 - Cannot award funding until NIBIB approves funding (hopefully in September?)
 - Poster(s) for RSNA authored by group/group members?
 - Physical/virtual phantoms and DRO? (**Paul and John will consider this**)
 - Other ideas?
 - If Rathan is ready and willing, update from the test-retest subgroup.
 - Allow time for group questions and discussion.
 - Seek volunteers from subgroups to review their respective section and send feedback (other sections if time!)
 - Test-retest: Rathan group lead
 - Site qualification: Greg Klein group lead (**Greg will review**)

- c. PET physics: Paul Kinahan and John Sunderland are group leads
 - d. Image analysis: Dawn Matthews group lead (**Dawn will review**)
 - e. Subject Preparation & Exam Performance with Radiotracer manufacturers to review
 - i. Seek a volunteer from Avid/Lilly, GE, Piramal and Navidea (**No one on the call; Anne will follow-up**)
4. Sections that need most attention
- a. Claim (Rathan and group)
 - b. References for Sections 3.4.2.1, 3.4.3.1, 3.4.3.1.1 and 3.4.3.2.2 (post-processing)
 - i. Dawn supplied these but for clarity purposes were left out of this version. Just need to add them back in.
 - c. Section 4.4 – Performance assessment: Image Analysis Workstation
 - i. Currently is for PET FDG Tumor Imaging
 - ii. Needs to be re-written for PET Amyloid Imaging
 - iii. Anyone want to take the lead? (Dawn will give feedback)
 - d. References – we have some listed, but they need to be edited, updated and referenced in main body of Profile
 - e. 3.6.3 Amyloid-PET Acquisition Scanner
 - i. Volunteer to write more requirements/suggestions for using 68-Ge transmission sources for dedicated PET scanners (HR+ or HRRT for example, **Greg can work with Bob Koepp on this language**)
 - f. Other – discussion of partial volume section, not clear what we mean. Profile should state clearly that we are **NOT** recommending this correction
 - i. Consider recommending correction for spill-in for WM
 - ii. Kirk Frey will give feedback on this section of Profile
 - iii. Currently, there is not a validated method for PVC. Therefore, remain in realm of research until this happens. Consider for future Profile versions.
5. Mutually agree to a date for first-round Profile feedback
- a. Initial suggestion is **September 11th**: please send Excel spreadsheet to ericasperlman@gmail.com
6. Discuss items that still need to be addressed
7. Discuss related opportunities
- a. Status of our relationship with GAAIN
 - i. MOU signed, QIBA is an affiliate of GAAIN
 - ii. Can distribute the MOU to group
 - iii. How to leverage this relationship?
 - 1. At appropriate time in our Profile drafting, request feedback from them?
 - 2. Can they help us now in our Claim language?
 - 3. Centiloid – work with them in the future to incorporate this in future versions of Profile
 - a. ADNI 3 is stressing using Centiloids
 - b. Is there any reason to EXCLUDE using Centiloids in the Profile?
 - i. Current version of Profile is only a longitudinal claim, no cross-sectional claim.
 - ii. Add language to Centiloid portion Profile, explaining above point
 - 1. Put Centiloids in context of our Profile (not needed for longitudinal claim), they are most useful for cross-sectional claims
 - 2. Confirm above point with a Centiloid leader
 - c. Are there other organizations we should include in our drafting process?
 - i. GAAIN
 - ii. RSNA has a list of organizations and individuals, work with RSNA staff

8. Next QIBA calls:

- **August 21:** SPECT Biomarker Ctte
- **August 28:** [Combined NM](#) Biomarker Committees
- **Sept 4:** FDG-PET BC
- **Sept 11:** Amyloid BC
- **Sept 18:** SPECT BC
- **Sept 25:** [Combined NM](#) BCs